Figitumumab

Drug Profile

Figitumumab

Alternative Names: Anti-IGF-1R monoclonal antibody - Pfizer; CP-751,871

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastrointestinal cancer; Gynaecological cancer; Multiple myeloma; Non-small cell lung cancer; Prostate cancer; Rheumatoid arthritis; Sarcoma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 02 Mar 2011 Discontinued - Phase-I for Multiple myeloma in USA (IV)
  • 28 Feb 2011 Discontinued - Phase-I for Solid tumours in Canada (IV)
  • 28 Feb 2011 Discontinued - Phase-I for Solid tumours in Finland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top